Fig. 3. Safety of desensitizations. (A) The overall number and severity of breakthrough reactions occurring during all desensitization from 2007 to 2010 at Brigham and Women's Hospital/Dana-Farber Cancer Institute is shown as a total of all desensitizations (2177) along with (B) specific data for carboplatin, rituximab, and paclitaxel, the most commonly desensitized drugs. (C) Breakdown of breakthrough reactions for all desensitizations. Adapted from Sloane, et al. J Allergy Clin Immunol Pract 2016;4:497-504, with permission of Elsevier [32].